ArticleFrontiers in genetics2019
Linc00662 Promotes Tumorigenesis and Progression by Regulating miR-497-5p/AVL9 Axis in Colorectal Cancer.
Article in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A pan-cancer analysis of the prognostic value of long non-coding RNA LINC00662 in human cancers.Frontiers in genetics · 2022Pooled it
- Dysregulation of noncoding RNA in chordoma; implications in identifying potential targets for novel therapeutic approaches.Molecular biology reports · 2024Review
- Colorectal cancer with low SLC35A3 is associated with immune infiltrates and poor prognosis.Scientific reports · 2024Article
- LINC00662 promotes melanoma progression by competitively binding miR-107 and activating the β-catenin signaling pathway.International journal of medical sciences · 2024Article
- Circ_0067717 promotes colorectal cancer cell growth, invasion and glutamine metabolism by serving as a miR-497-5p sponge to upregulate SLC7A5.Histology and histopathology · 2023Article
- LINC00662 enhances cell progression and stemness in breast cancer by MiR-144-3p/SOX2 axis.Cancer cell international · 2022Article
- Article
- MiR-363-3p promotes prostate cancer tumor progression by targeting Dickkopf 3.Journal of clinical laboratory analysis · 2022Article
- Gastrodin promotes the regeneration of peripheral nerves by regulating miR-497/BDNF axis.BMC complementary medicine and therapies · 2022Article
- Knockdown of lncRNA LINC00662 suppresses malignant behaviour of osteosarcoma cells via competition with miR-30b-3p to regulate ELK1 expression.Journal of orthopaedic surgery and research · 2022Article
- AVL9 promotes colorectal carcinoma cell migration via regulating EGFR expression.Biological procedures online · 2022Article
- miR-497-5p-RSPO2 axis inhibits cell growth and metastasis in glioblastoma.Journal of Cancer · 2022Article
- Pro-Angiogenesis Role of LINC00662 From Esophageal Squamous Cell Carcinoma Cells-Derived Extracellular Vehicles.Frontiers in bioengineering and biotechnology · 2022Article
- Decreased E2F2 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Colorectal Cancer.Journal of Cancer · 2022Article
- HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.Oncogene · 2021Article
- hsa_circ_0058357 acts as a ceRNA to promote non‑small cell lung cancer progression via the hsa‑miR‑24‑3p/AVL9 axis.Molecular medicine reports · 2021Article
- The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.FEBS open bio · 2021Article
- Biomarker potentials of miRNA-associated circRNAs in breast cancer (MCF-7) cells: an in vitro and in silico study.Molecular biology reports · 2021Article
- Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome.International journal of molecular sciences · 2021Review
- Identification and Validation of EMT-Related lncRNA Prognostic Signature for Colorectal Cancer.Frontiers in genetics · 2021Article
Corrections and comments
- Retraction · 2026-01-15Concerns/Issues about Image · Investigation by Journal/Publisher · Investigation by Third Party · · See also: https://pubpeer.com/publications/EA6178E3D8361D0299CE69144A6B83
- Retracted
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, multiple lines of evidence have demonstrated that linc00662 serves as an oncogene in various cancers. However, the exact mechanism of oncogenesis mediated by linc00662 in colorectal cancer (CRC) remains unknown. In this study, we aimed to explore the biological role of linc00662 in the regulation of CRC progression.
methodsBoth gene expression omnibus (GEO) and the cancer genome atlas (TCGA) datasets were used to evaluate the expression of linc00662. RT-qPCR was used to analyze the expression of linc00662, miR-497-5p, and
resultsIn this study, we found that the expression of linc00662 was significantly upregulated in CRC tissues compared to normal tissues and positively correlated with tissue differentiation, T stage, and lymphatic metastasis. Further, our data showed that the expression of linc00662 was positively associated with lymph node metastasis, TMN stage, and poor-moderate differentiation. Patients with higher linc00662 expression level were more likely to have poorer overall survival. Knockdown of linc00662 inhibited CRC cell growth, induced cell apoptosis, triggered cell cycle arrest at G2/M phase, and suppressed cell migration and invasion through regulating the EMT pathway. Further, mechanistic studies revealed that knockdown of linc00662 significantly reduced the expression of
conclusionsLinc00662 was significantly upregulated in CRC, and mediated CRC progression and metastasis by competing with miR-497-5p to modulate the expression of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.